Apitope's ATX-MS-1467 shows positive immunological data in Multiple Sclerosis
Final Phase I/IIa data shows safety and tolerability, plus efficacy
05-Feb-2008 -
Apitope Technology (Bristol) Ltd., developer of peptide-based therapies for autoimmune diseases and allergy, announces today final results of a Phase I/IIa clinical trial of ATX-MS-1467 to treat Multiple Sclerosis (MS). Immunological analyses showed a significant down regulation of the T-cell ...
allergies
autoimmune diseases
clinical trials
+4